You know, those halcyon days of last week.
Oh, there was also some alleged insurance fraud going on in the opioid-pushing.
Rep. Chris Collins should have just started a hedge fund.
The Second Circuit Court of Appeals would like The Shkrelster to just finish up that prison sentence in silence.
The company, whose FDA-approved products include the myeloma drug Darzalex and the chronic leukemia drug Arzerra, hopes to launch its own proprietary product by 2025.
We can taste this one it's so perfect.
Giving a thinly-veiled anonymous interview on a contraband cellphone to brag about how he is illegally running a pharma business from prison reminds us why we miss this guy.
This even applies to pharma apparently.
The Life Sciences Law Firm Index identifies the most active and relevant firms for life science companies.
Trump's vast array of conflicts of interest provide a profit opportunity for the savvy investor.
How do you put a price on failure?
Weapons manufacturers and private prisons are loving this whole Trump thing today.
Although this could give someone an idea about how to fix Chipotle.
Heather Bresch seems to have known that Heather Bresch's management was going to have an adverse effect on Mylan stock.
That brings Martin's grand total to eight...so far.
We hope Bill Ackman is meditating today.
If you're going to talk sh!t about Valeant, just assume that Bill is listening.
Looks like Martin is going to need to find a dope rhyme for "Securities fraud."